Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of lorundrostat in uncontrolled and resistant hypertension
2023-506425-12-00Phase 3Completed
- Sponsor
- Mineralys Therapeutics
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in hypertension (HTN) and resistant hypertension (RH) comparing Lorundrostat with Placebo (2 arms). Started Apr 2024; status: completed.
02
Drugs
lorundrostat
03
Conditions
hypertension (HTN)resistant hypertension (RH)
Beyond the preview
Go deeper on 2023-506425-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506425-12-00.